Boehringer Ingelheim has received UK marketing authorisation for RenuTend - the first licensed treatment to improve healing of tendon injuries and suspensory ligaments in horses.

Renutend contains primed mesenchymal stem cells (MSCs) which Boehringer says are specifically targeted to reduce scar tissue formation so horses can return to the intended level of performance, with a reduced risk of re-injury1.

According to the company, a single dose decreases scar tissue formation with consistent and proven results 2.

RenuTend is administered by intralesional injection and complements Boehringer Ingelheim’s other equine stem cell product Arti-Cell Forte, which is authorised to treat mild to moderate recurrent lameness associated with non-septic joint inflammation in horses. 

RenuTend will be available in September this year.

In the meantime, Boehringer is encouraging veterinary surgeons to register their interest with their BIAH representative or call 01344746960 in order to get updates or product information as soon as it becomes available.


  1. RenuTend® Study Report 1 – Re-injury Rate. Boehringer Ingelheim Animal Health. 2022
  2. Depuydt, E., Broeckx, S.Y., Hecke, L.V., Chiers, K., Brantegem, L.V., Schie, H. van, Beerts, C., Spaas, J.H., Pille, F., Martens, A., 2021. The Evaluation of Equine Allogeneic Tenogenic Primed Mesenchymal Stem Cells in a Surgically Induced Superficial Digital Flexor Tendon Lesion Model. Frontiers Vet Sci 8, 641441.

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.